La. Jury Hits J&J With $258M Verdict In Risperdal Suit
A Louisiana jury has smacked a Johnson & Johnson unit with a $257.7 million verdict in the state's suit against the company for downplaying the link between its antipsychotic drug Risperdal...To view the full article, register now.
Already a subscriber? Click here to view full article